|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
La Jolla Pharmaceutical Co (LJPC) |
|
|
$6.22 0.00 (0.00%) as of 4:30 Thu 8/18
|
|
Download |
|
|
| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
27,470,000 |
| Market
Cap: |
170.86(M) |
| Last
Volume: |
2,592,323 |
Avg
Vol: |
2,585,089 |
| 52
Week Range: |
$6.22 - $6.22 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hearne Michael S |
Chief Financial Officer |
• – – |
2020-06-02 |
4 |
B |
$4.88 |
$1,237,060 |
I/I |
253,553 |
8,333,898 |
1.99 |
-13% |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-05-29 |
4 |
A |
$4.01 |
$822 |
D/D |
205 |
81,771 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2020-05-29 |
4 |
A |
$4.01 |
$329 |
D/D |
82 |
5,067 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-05-29 |
4 |
A |
$4.01 |
$1,969 |
D/D |
491 |
9,942 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2020-05-15 |
4 |
A |
$5.86 |
$328 |
D/D |
56 |
4,985 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-05-15 |
4 |
A |
$5.86 |
$820 |
D/D |
140 |
81,566 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-05-15 |
4 |
A |
$5.86 |
$1,963 |
D/D |
335 |
9,451 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-04-30 |
4 |
A |
$6.17 |
$1,968 |
D/D |
319 |
9,116 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2020-04-30 |
4 |
A |
$6.17 |
$327 |
D/D |
53 |
4,929 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-04-30 |
4 |
A |
$6.17 |
$821 |
D/D |
133 |
81,426 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-04-15 |
4 |
A |
$5.61 |
$1,964 |
D/D |
350 |
8,797 |
|
- |
|
| Wellinghoff Darryl |
Chief Commercial Officer |
• – – |
2020-04-15 |
4 |
A |
$5.61 |
$191 |
D/D |
34 |
9,504 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-04-15 |
4 |
A |
$5.61 |
$819 |
D/D |
146 |
81,293 |
|
- |
|
| Mulroy Dennis |
Chief Financial Officer |
• – – |
2020-04-15 |
4 |
A |
$5.61 |
$325 |
D/D |
58 |
4,876 |
|
- |
|
| Wellinghoff Darryl |
Chief Commercial Officer |
• – – |
2020-03-31 |
4 |
A |
$3.57 |
$1,639 |
D/D |
459 |
9,470 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-03-31 |
4 |
A |
$3.57 |
$818 |
D/D |
229 |
81,147 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-03-31 |
4 |
A |
$3.57 |
$589 |
D/D |
165 |
8,447 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-03-13 |
4 |
A |
$3.40 |
$588 |
D/D |
173 |
8,282 |
|
- |
|
| Wellinghoff Darryl |
Chief Commercial Officer |
• – – |
2020-03-13 |
4 |
A |
$3.40 |
$1,642 |
D/D |
483 |
9,011 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-03-13 |
4 |
A |
$3.40 |
$819 |
D/D |
241 |
80,918 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-02-28 |
4 |
A |
$5.78 |
$821 |
D/D |
142 |
80,677 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-02-28 |
4 |
A |
$5.78 |
$590 |
D/D |
102 |
8,109 |
|
- |
|
| Wellinghoff Darryl |
Chief Commercial Officer |
• – – |
2020-02-28 |
4 |
A |
$5.78 |
$1,642 |
D/D |
284 |
8,528 |
|
- |
|
| Chawla Lakhmir S |
Chief Medical Officer |
• – – |
2020-02-14 |
4 |
A |
$7.14 |
$593 |
D/D |
83 |
8,007 |
|
- |
|
| Rolke James |
Chief Scientific Officer |
• – – |
2020-02-14 |
4 |
A |
$7.14 |
$821 |
D/D |
115 |
80,535 |
|
- |
|
333 Records found
|
|
Page 5 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
